Physician Hospital Organization



Beth Israel Lahey Health GLP-1RA Conversion Guide

11/2022

The purpose of this guide is to assist with the conversion of GLP1-RA's due to current product shortages. Assessment of equivalent dose is based on head-to-head clinical trials when available and/or clinical experience. This guide does not replace clinical judgment.

Drug	Frequency	ency Equivalent Dose (A1c Reduction)						
Dulaglutide (Trulicity)1	Weekly		0.75 mg	1.5 mg	3 mg ⁴	4.5 mg ⁴		
Semaglutide (Ozempic) ¹	Weekly	0.25 mg ²		0.5 mg	1 mg	2 mg		
Liraglutide (Victoza)1	Daily	0.6 mg ²	1.2 mg	1.8 mg				
Oral Semaglutide (Rybelsus)	Daily	3 mg ²	7 mg	14 mg				
Exenatide (Bydureon BCise)3	Weekly		2 mg ³					
Exenatide (Byetta) Rarely used, not recommended to initiate	Twice Daily	5 mcg	10 mcg					
Tirzepatide (Mounjaro)	Given novel mechanism (GIP/GLP1), consider starting at initiation dose of 2.5 mg ² once weekly x 4 weeks, then increase to 5 mg once weekly. Continue to increase by 2.5 mg increments every 4 weeks as tolerated for additional glycemic control. Not currently indicated for ASCVD risk reduction.							


¹ Agents with ASCVD evidence in bold

² Starting doses not considered therapeutic. Increase dose after indicated duration, if tolerating.

³Increased risk of injection site reactions vs. Trulicity, Ozempic, and Victoza.

⁴ Additional A1c reduction not as significant as weight reduction at higher doses

Physician Hospital Organization





Physician Hospital Organization

Summary of Clinical Evidence and Comparison Chart

Trial	Active Comparators	Background Regimen	Time Point for efficacy, weeks	A1c reduction	Weight loss, kg	Adverse Effects: D/C due to GI adverse events
Award 11	Trulicity 1.5 mg vs. Trulicity 3 mg	Metformin	36	Trulicity 1.5 mg: -1.5% Trulicity 3 mg: - 1.6% not statistically sig	-8.4 lbs (3 mg)	3.1%
Award 11	Trulicity 1.5 mg vs. Trulicity 4.5 mg	Metformin	36	Trulicity 4.5 mg: -1.8% P <0.001	-10.1 lbs (4.5 mg)	3.1%
SUSTAIN 7	Ozempic 1 mg vs. Trulicity 1.5 mg	Metformin	40	Ozempic 1 mg: - 1.6% Trulicity 1.5 mg: - 1.3% p=0.0004	Ozempic 1 mg: -12.8 lbs Trulicity 1.5 mg: -6.2 lbs	6% (vs. 5% Trulicity)
SUSTAIN FORTE	Ozempic 1 mg vs. Ozempic 2 mg	Metformin +/- SFU	40	Ozempic 1 mg: - 1.9% Ozempic 2 mg: -2.1% P < 0.01	Ozempic 2 mg: -14.2 Ozempic 1 mg: -12.5 lbs	Not documented. Nausea 14% vs. 15%
SURPASS-2	Ozempic 1 mg vs. Mounjaro 5 mg, 10 mg, 15 mg	Metformin	40	Mounjaro 5 mg: -2% Mounjaro 10 mg: -2.2% Mounjaro 15 mg: -2.3% Ozempic 1 mg: - 1.9%	Mounjaro 5 mg: -17 lbs Mounjaro 10 mg: -21 lbs Mounjaro 15 mg: -25 lbs Ozempic 1 mg: -13 lbs	Mounjaro 5 mg: 2.8% Mounjaro 10 mg 4.3% Mounjaro 15 mg: 4.3% Ozempic 1 mg: 3.2%

Physician Hospital Organization

References:

- Almandoz J, Lingvay I, Morales J et al. Switching between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clin Diabetes. 2020; 38 (4).390-402.
- Frias, Juan P., et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021; 44(3): 765-773.
- Pratley RE, Aroda VR, Lingvay I, et al, on behalf of the SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly
 in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol.
 2018;6(4):275-286.
- Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574.
- Frias JP, Davies MJ, Rosenstock J, et al.; for the SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6 suppl):503-515